NOW AVAILABLE: For the Asthma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q1 2017.

Overall, brands within the asthma market focused on patient access by promoting formulary coverage and cost saving options for patients. AstraZeneca’s Symbicort was the promotional leader with 31% of the asthma market, followed closely by GSK’s Breo Ellipta, which heavily utilized the “Missing Piece” campaign in DTC materials. A portfolio of GSK’s Ellipta franchise emphasized once-daily dosing. AstraZeneca announced that Symbicort is now approved for pediatric patients as young as 6 and that a wide range of commercially insured patients will continue to have access to the $0 Guarantee Program in 2017. A portfolio of GSK’s Ellipta franchise emphasized once-daily dosing. Additional insights into marketing strategies and channel utilization are available in the full Q1 report.

Q1-2017-Asthma

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com